SEA-TGT

N/A

Report date: 2024/02/23 20:00:47

Base Information

Drug NameSEA-TGT
Drug Alias NameSGN-TGTSEA-TGTSGN-TIGIT
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSkin MelanomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen Inc
Active IndicationsN/A
Inactive IndicationsSkin MelanomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A